Premium
Is there an established role for immunotherapy for any of our surgical cancers?
Author(s) -
Elias E. George
Publication year - 1991
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.2930480302
Subject(s) - medicine , immunotherapy , modalities , radiation therapy , therapeutic modalities , cancer , adjuvant , chemotherapy , oncology , hormonal therapy , treatment modality , intensive care medicine , breast cancer , social science , sociology
Despite major advances in the management of the patient and in surgical and radiation therapy, cancer deaths continue to occur secondary to widespread metastases. Therefore, systemic treatments in the form of chemotherapy, hormonal therapy, and immunotherapy are constantly being investigated, both as adjuvant to the local therapeutic modalities, as well as therapeutically for unresectable metastases. While the first two systemic modalities have established themselves in cancer management, immunotherapy has been lagging behind for several reasons.